Table 1.
Clinical and demographic data of the patients
| Demographics | Patients (n=3255) |
|---|---|
| Age, mean ± SD (range) | 37.78±9.37 (18–62) |
| Gender | |
| Female | 2356 (72.4%) |
| Male | 899 (27.6%) |
| Disease duration (years, mean ± SD, range) | 8.85±6.93 (1–29) |
| Clinical Phenotype | |
| Relapsing-Remitting MS | 28.1% |
| Secondary-Progressive MS | 3.6% |
| Primary-Progressive MS | 6.0% |
| “I do not know the clinical phenotype” | 62.1% |
| Current treatment | |
| Interferon beta | 20.1% |
| Glatiramer acetate | 12.7% |
| Teriflunomide | 9.4% |
| Dimethyl fumarate | 12.7% |
| Natalizumab | 4% |
| Ocrelizumab | 15.2% |
| Alemtuzumab | 0.4% |
| Other | 3.8% |
| No treatment | 16.6% |
| I do not know the treatment | 5.1% |
MS: Multiple sclerosis; SD: Standard deviation